Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New US FDA Generics Director Praises Industry, Encourages Partnerships

Executive Summary

Refuse-to-receive rates for ANDAs are down, suggesting sponsors better understand the standards for quality applications, Office of Generic Drugs Director Sally Choe says in first speech to industry.

You may also be interested in...



House Committee Clears Bills To Prevent Pay-For-Delay Deals, Assure Generic Access To Samples

Legislation on patent settlement agreements will not be retroactive; CREATES Act amended to give brand companies affirmative defense to litigation.

US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals

Agency will work past generic goal dates if approval can be achieved quickly thereafter, but now must create policy defining criteria for those situations.

Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says

Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel